BBS-Bioactive Bone Substitutes
0.472 EUR +1.94%BBS-Bioactive Bone Substitutes is a medical technology company. The company designs, develops and constructs biological implants for patients with bone defects and healing problems. The company's solutions are resold under the Artebone brand and are based on tricalcium phosphate (TCP) and bone protein, which stimulates the bone healing process. The company was founded in 2003 and is headquartered in Oulu.
Log in to see the recommendation and risk by Inderes
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Reisjärven Kunta | 13.9 % | 13.9 % |
Finha Capital | 12.1 % | 12.2 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Juliusz Rakowski | 18.12.2023 | 10,000EUR |
Jarmo Halonen | 18.12.2023 | 2,560EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 1.2 | 2.8 | 6.7 |
growth-% | 4,499.5 % | 537.6 % | 138.6 % | 139.3 % | ||||
EBITDA | -2.4 | -2.3 | -2.7 | -3.1 | -3.8 | -3.5 | -3.0 | -2.1 |
EBIT (adj.) | -2.6 | -2.6 | -3.0 | -3.4 | -4.0 | -4.0 | -3.6 | -2.7 |
EBIT | -2.6 | -2.6 | -3.0 | -3.4 | -4.0 | -4.0 | -3.6 | -2.7 |
Profit before taxes | -2.7 | -2.8 | -3.1 | -3.5 | -4.1 | -4.3 | -3.9 | -2.9 |
Net income | -2.7 | -2.8 | -3.1 | -3.5 | -4.1 | -4.3 | -3.9 | -2.9 |
EPS (adj.) | -0.42 | -0.40 | -0.32 | -0.18 | -0.21 | -0.22 | -0.20 | -0.15 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -60,775.0 % | -58,500.0 % | -68,150.0 % | -78,738.0 % | -2,088.3 % | -300.4 % | -108.9 % | -30.8 % |
EBIT-% (adj.) | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -2,197.0 % | -343.2 % | -128.9 % | -40.0 % |
EBIT-% | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -2,197.0 % | -343.2 % | -128.9 % | -40.0 % |
ROE | -59.6 % | -57.0 % | -78.2 % | -74.2 % | -135.9 % | 368.8 % | 73.9 % | 34.1 % |
ROI | -24.4 % | -23.1 % | -28.5 % | -31.6 % | -42.0 % | -44.6 % | -36.5 % | -24.2 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 3.90 | 1.79 | 1.05 | 0.49 | 0.47 | 0.47 | 0.47 | 0.47 |
Shares | 6.6 | 7.0 | 9.7 | 19.3 | 19.4 | 19.4 | 19.4 | 19.4 |
Market cap | 25.6 | 12.5 | 10.1 | 9.4 | 9.1 | 9.1 | 9.1 | 9.1 |
Enterprise value | 28.4 | 17.7 | 15.0 | 13.0 | 16.7 | 21.7 | 26.4 | 30.6 |
EV/S | 7,095.0 | 4,417.5 | 3,758.6 | 3,242.8 | 90.7 | 18.5 | 9.4 | 4.6 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 4.2 | 3.4 | 2.4 | 1.8 | 9.4 | - | - | - |
P/S | 6,407.2 | 3,131.2 | 2,533.8 | 2,359.1 | 49.7 | 7.8 | 3.3 | 1.4 |
Dividend yield | ||||||||
Equity ratio | 48.0 % | 34.6 % | 40.0 % | 48.2 % | 11.3 % | -34.8 % | -69.3 % | -85.5 % |
Gearing ratio | 45.2 % | 141.6 % | 114.7 % | 69.1 % | 773.7 % | -381.9 % | -241.2 % | -213.0 % |
Login required
This content is only available for logged in users
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.2 | ||||||
EBITDA | -1.5 | -1.7 | -3.1 | -1.9 | -2.0 | ||||
EBIT | -1.6 | -1.8 | -3.4 | -2.0 | -2.1 | ||||
Profit before taxes | -1.6 | -1.8 | -3.5 | -2.0 | -2.1 | ||||
Net income | -1.6 | -1.8 | -3.5 | -2.0 | -2.1 |
Login required
This content is only available for logged in users
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits